SecBot SecBot
8-K ·Filed Feb 25, 2026

UTHR

UNITED THERAPEUTICS Corp
BULLISH
Impact 7/10
Horizonweeks Processed8mo ago SEC0001082554-26-000007
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The sustained double-digit revenue growth, particularly in Tyvaso DPI, combined with strong profitability and ongoing share repurchases, suggests continued momentum. Traders should monitor the upcoming ADVANCE OUTCOMES and TETON-1 clinical trial readouts as potential catalysts for further upside.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$534.37
T+0 close · Feb 25, 2026 · via day close
Latest settled
+5.53%
T+60 · $563.93
Vs SPY
−1.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 25 $534.37entry
  2. T+1 · 9mo ago −5.84%α −5.29% · $503.18
  3. T+5 · 9mo ago −8.78%α −7.68% · $487.47
  4. T+20 · 8mo ago +1.28%α +6.52% · $541.22
  5. T+60 · 6mo ago +5.53%α −1.42% · $563.93
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

United Therapeutics reported record full-year 2025 revenue of $3.18 billion, up 11% year-over-year, driven by strong performance from Tyvaso DPI and Orenitram. Net income increased to $1.33 billion, and the company maintained its share repurchase program with $2 billion in accelerated buybacks. Management reaffirmed expectations for durable double-digit revenue growth.

Key Financial Metrics

Revenue
$3.2K
+11.0% YoY
EPS
$27.86

Key Facts

  • Full-year 2025 revenue reached $3.18 billion, up 11% from $2.88 billion in 2024
  • Tyvaso DPI revenue grew 25% to $1.29 billion, driven by patient growth and Medicare Part D benefit redesign
  • Net income increased 12% to $1.33 billion, with diluted EPS of $27.86
  • Company executed $2 billion in accelerated share repurchases ($1 billion in August 2025 and $1 billion in March 2024)
  • Management maintained guidance for durable double-digit revenue growth

Financial Impact

Revenue growth of $305.3 million and net income growth of $139.6 million year-over-year

revenueepsnet incomedilution

Segment Breakdown

SegmentRevenueGrowth
Tyvaso DPI$1.3K+25.0%
Orenitram$496.90+14.0%
Remodulin$526.80-2.0%

Risk Factors

  • Revenue declines in Remodulin (-2% YoY) and Unituxin (-5% YoY) could indicate product lifecycle challenges
  • Increased R&D spending (up 14% to $550 million) may pressure future margins if not offset by new product approvals
  • Forward-looking statements about clinical trials and revenue growth are subject to significant risks and uncertainties

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001082554-26-000007
Document: uthr-20260225.htm0001082554-26-000007
Document: 0001082554-26-000007-index-headers.html0001082554-26-000007
Document: 0001082554-26-000007-index.html0001082554-26-000007
Document: 0001082554-26-000007.txt0001082554-26-000007

Track record

123 reports on UTHR

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 4 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 3/10 Entry $587.88 Now $587.88 +0.00% settles Nov 24
  2. Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
  3. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
  4. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
  5. Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  6. Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  7. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
  8. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  9. Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  10. Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
Showing 10 of 123

US Market Status

Market Closed · Opens in 8h 30m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 25, 2026